Clinical

Dataset Information

0

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients


ABSTRACT: Objectives: 1. To estimate progression-free survival (PFS) at 12 months in subjects with metastatic colorectal cancer who receive FOLFIRI [folinic acid (leucovorin or LV), 5-Fluorouracil (5-FU), irinotecan) plus bevacizumab as first line treatment. 2. To determine the objective response rate and the duration of objective response in this population. 3. To assess overall survival (OS) in this population. 4. To measure the effect of treatment on intratumoral blood volume and microvascular permeability by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in consenting patients in whom it is technically feasible. 5. To correlate plasma proteomics with response. 6. To assess the safety of this regimen.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2031080 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2065134 | ecrin-mdr-crc
2024-01-31 | GSE223282 | GEO
| 2520879 | ecrin-mdr-crc
2021-09-08 | GSE183603 | GEO
2013-11-01 | GSE51351 | GEO
| PRJNA596437 | ENA
| PRJNA608537 | ENA
2012-08-16 | E-GEOD-36562 | biostudies-arrayexpress
2024-01-23 | GSE253502 | GEO
2012-08-16 | GSE36562 | GEO